National Pregnancy Registry for Psychiatric Medications©

Click here for Participation information

The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, and atypical antipsychotics that many people take during pregnancy to treat a wide range of mood, anxiety, executive function, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy, as current data is limited.

If you are pregnant and have taken an antidepressant, ADHD medication, or atypical antipsychotic, please click the participation information button above. Individuals with a history of psychiatric illness who are pregnant and have not taken an antidepressant, ADHD medication, or atypical antipsychotic are also welcome to enroll in the Registry.

The National Pregnancy Registry for Atypical Antipsychotics

The National Pregnancy Registry for Antidepressants

The National Pregnancy Registry for ADHD Medications

The National Pregnancy Registry for Sedative-Hypnotics and Other Sleep Medications

Viguera, A.C., Vanderkruik, R., Gaccione, P. et al. Breastfeeding practices among women taking second-generation antipsychotics: findings from the National Pregnancy Registry for Atypical Antipsychotics. Arch Womens Ment Health (2021).

Viguera AC, Freeman MP, Góez-Mogollón L, et al. Reproductive safety of second-generation antipsychotics: updated data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. J Clin Psychiatry. 2021;82(4):20m13745.

Freeman, M.P., Viguera, A.C., Góez-Mogollón, L. et al. Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Arch Womens Ment Health 24, 659–667 (2021).

Freeman MP, Goez-Mogollon L, Sosinsky AZ, Church TR, McElheny SA, Viguera AC, Cohen LS. The impact of obesity on pregnancy outcomes among women with psychiatric disorders: Results from a prospective pregnancy registry. Journal of Psychosomatic Research. 2019; 123:109735.

Freeman MP, Sosinsky AZ, Góez-Mogollón L, Savella GM, Moustafa D, Viguera AC, Cohen LS. Gestational weight gain and pre-pregnancy body mass index associated with second-generation antipsychotic use during pregnancy. Psychosomatics. 2018 Mar – Apr;59(2):125-134. doi: 10.1016/j.psym.2017.09.002. Pubmed PMID: 29078988

Cohen LS, Góez-Mogollón L, Sosinsky AZ, Savella GM, Viguera AC, Chitayat D, Hernández-Díaz S, Freeman MP. Risk of Major Malformations in Infants Following First Trimester Exposure to Quetiapine. Am J Psychiatry. 2018 Aug 16:appiajp201818010098. doi: 10.1176/appi.ajp.2018.18010098. [Epub ahead of print] PubMed PMID: 30111186.

Freeman MP, Farchione T, Yao L, Sahin L, Taylor L, Huybrechts KF, Nonacs R, Sosinsky AZ, Viguera AC, Cohen LS. Psychiatric Medications and Reproductive Safety: Scientific and Clinical Perspectives Pertaining to the US FDA Pregnancy and Lactation Labeling Rule. J Clin Psychiatry. 2018 Jul 17;79(4). pii: 18ah38120. doi: 10.4088/JCP.18ah38120. PubMed PMID: 30153401.

Freeman MP, Góez-Mogollón L, McInerney KA, Davies AC, Church TR, Sosinsky AZ, Noe OB, Viguera AC, Cohen LS. Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: Results from a prospective registry of women with psychiatric disorders. Gen Hosp Psychiatry. 2018 May 29;53:73-79. doi: 10.1016/j.genhosppsych.2018.05.010. [Epub ahead of print] PubMed PMID: 29958100.

Park Y, Hernandez-Diaz S, Bateman BT, Cohen JM, Desai RJ, Patorno E, Glynn RJ, Cohen LS, Mogun H, Huybrechts KF. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. Am J Psychiatry. 2018 Jun 1;175(6):564-574. doi: 10.1176/appi.ajp.2018.17040393. Epub 2018 May 7. PubMed PMID: 29730938; PubMed Central PMCID: PMC5988929.

Panchaud A, Hernandez-Diaz S, Freeman MP, Viguera AC, MacDonald SC, Sosinsky AZ, Cohen LS. Use of atypical antipsychotics in pregnancy and maternal gestational diabetes. J Psychiatr Res. 2017 Dec; 95:84-90.

Freeman MP, Sosinsky AZ, Goez-Mogollon L, Savella GM, Moustafa D, Viguera AC, Cohen LS.  Gestational Weight Gain and Pre-pregnancy Body Mass Index Associated With Second-Generation Antipsychotic Drug Use During Pregnancy.   Psychosomatics. 2017 Sep 21.

Sosinsky AZ, Freeman MP, Savella GM, Cheng LJ, Viguera AC, Cohen LS. Delusional Pregnancy Presenting to the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. J Clin Psychopharmacol. 2017 Aug;37(4):472-474.

Huybrechts KF, Hernández-Díaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ, Cohen JM, Panchaud A, Cohen L, Bateman BT.  Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations.  JAMA Psychiatry. 2016 Sep 1;73(9):938-46.

Patorno E, Huybrechts KF, Bateman BT, Cohen JM, Desai RJ, Mogun H, Cohen LS, Hernandez-Diaz S.  Lithium Use in Pregnancy and the Risk of Cardiac Malformations. N Engl J Med. 2017 Jun 8; 376(23):2245-2254

Freeman MP, Sosinsky AZ, Moustafa D, Viguera AC, Cohen LS. Supplement Use by Women during Pregnancy: Data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Arch Women’s Mental Health. 2016 Jun;19(3):437-41

Freeman MP. Psychotropic medication use during pregnancy: changes to the labeling system and the importance of exposure registries. Journal of Clinical Psychiatry. 2015;76(7):990-991.

Cohen LS, Viguera AC, McInerny KA, Freeman MP, et al. Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Am J Psychiatry. 2015 Oct 6.

Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, Mogun H, Levin R, Kowal M, Setoguchi S, Hernández-Díaz S. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014 Jun 19; 370(25):2397-407.

Cohen LS. Drugs, Pregnancy and Lactation: Atypical Antipychotics During Pregnancy. ObGyn News, April 2008

Cohen LS, Viguera AC, McInerny KA, Freeman MP, et al. Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Am J Psychiatry 2015.

Required Sponsorship Disclosures:

Current Sponsors: Alkermes, Inc. (2016-Present); Johnson & Johnson/Janssen Pharmaceuticals, Inc (2019-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Sage Therapeutics (2019-Present); Sunovion Pharmaceuticals, Inc. (2011-Present); Supernus Pharmaceuticals (2021-Present); Teva Pharmaceutical Industries Ltd. (2018-Present).

Past Sponsors: Forest/Actavis/Allergan (2016-2018, declined to sponsor: 2018-Present); Aurobindo Pharma (2020-2022, declined to sponsor: 2022-Present); AstraZeneca Pharmaceuticals (2009-2014, declined to sponsor: 2014-Present); AuroMedics Pharma LLC (2021-2022, declined to sponsor: 2022-Present); Ortho-McNeil-Janssen Pharmaceuticals, Inc (2009-2014, declined to sponsor: 2015-Present); Pfizer, Inc. (2009-2011, declined to sponsor: 2012-Present).

Declined to sponsor: Apotex Inc.; Eli Lilly and Company; Novartis Pharmaceuticals; Vanda Pharmaceuticals Inc.

Funding Information: Manufacturers of psychiatric medications have been approached regarding funding of the National Pregnancy Registry. Regardless of which entities have supported this initiative, all medications in this class are studied. For more information on how to sponsor the Registry, please see the contact information below.